Trial Profile
Bioequivalence Study Comparing the Pharmacokinetics and Pharmacodynamics of LY2963016 With Insulin Glargine in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 01 Dec 2011 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.